exemestane
Selected indexed studies
- Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. (J Clin Oncol, 2023) [PMID:36521078]
- Exemestane. (Drugs, 1999) [PMID:10551437]
- ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. (Clin Cancer Res, 2020) [PMID:32546646]
_Worker-drafted node — pending editorial review._
Connections
exemestane is a side effect of
Sources
- Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. (2023) pubmed
- Exemestane. (1999) pubmed
- ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. (2020) pubmed
- Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence. (2022) pubmed
- Exemestane: a milestone against breast cancer. (2007) pubmed
- Exemestane (FCE 24304), a new steroidal aromatase inhibitor. (1992) pubmed
- Exemestane: a novel aromatase inactivator for breast cancer. (2000) pubmed
- Exemestane: a review of its use in postmenopausal women with advanced breast cancer. (2000) pubmed
- Analytical Interference of Exemestane With Androstenedione Immunoassays. (2025) pubmed
- Exemestane in advanced breast cancer. (2000) pubmed